461 related articles for article (PubMed ID: 33852056)
1. Immunotherapy in Cervical Cancer.
Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
[TBL] [Abstract][Full Text] [Related]
2. Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Crafton SM; Salani R
Clin Ther; 2016 Mar; 38(3):449-58. PubMed ID: 26926322
[TBL] [Abstract][Full Text] [Related]
3. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
4. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
5. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
6. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
Eskander RN; Tewari KS
Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
9. Advances in immunotherapy for cervical cancer.
Wendel Naumann R; Leath CA
Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
[TBL] [Abstract][Full Text] [Related]
10. Major clinical research advances in gynecologic cancer in 2017.
Suh DH; Kim M; Lee KH; Eom KY; Kjeldsen MK; Mirza MR; Kim JW
J Gynecol Oncol; 2018 Mar; 29(2):e31. PubMed ID: 29468855
[TBL] [Abstract][Full Text] [Related]
11. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
12. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer.
Kwon MJ
Arch Pharm Res; 2022 Sep; 45(9):597-617. PubMed ID: 35982262
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
15. The immunotherapy revolution in genitourinary malignancies.
U Gandhy S; Madan RA; Aragon-Ching JB
Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
17. Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Miller RE; Lewis AJ; Powell ME
Br J Radiol; 2021 Dec; 94(1128):20210002. PubMed ID: 33882241
[TBL] [Abstract][Full Text] [Related]
19. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
20. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]